$891.6 M

CBAY Mkt cap, 16-May-2019
CymaBay Therapeutics Net income (FY, 2018)-72.5 M
CymaBay Therapeutics EBIT (FY, 2018)-72.5 M
CymaBay Therapeutics Cash, 31-Dec-201849 M

CymaBay Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

24.4m7.7m10.5m23.1m49.0m

Current Assets

32.2m42.8m18.5m103.5m181.6m

PP&E

3.0k64.0k77.0k69.0k2.9m

Total Assets

32.5m43.1m19.4m104.2m186.7m

Accounts Payable

697.0k1.0m899.0k1.3m2.0m

Current Liabilities

9.5m6.1m9.3m16.3m14.4m

Total Liabilities

13.9m15.0m15.4m19.3m16.3m

Additional Paid-in Capital

367.4m424.4m426.9m535.5m693.5m

Retained Earnings

(348.8m)(396.3m)(423.0m)(450.5m)(523.1m)

Total Equity

18.6m28.1m3.9m84.9m170.4m

Financial Leverage

1.7 x1.5 x4.9 x1.2 x1.1 x

CymaBay Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2016FY, 2017FY, 2018

Net Income

(10.1m)(26.7m)(27.6m)(72.5m)

Depreciation and Amortization

55.0k29.0k35.0k105.0k

Accounts Receivable

(59.0k)(5.0m)

Accounts Payable

40.0k(109.0k)412.0k662.0k

Cash From Operating Activities

(8.5m)(23.4m)(19.6m)(54.9m)

Purchases of PP&E

(42.0k)(27.0k)(529.0k)

Cash From Investing Activities

(6.2m)27.1m(67.5m)(54.1m)

Cash From Financing Activities

31.4m(986.0k)99.7m135.0m

Interest Paid

74.0k866.0k666.0k231.0k

Quarterly

USDQ1, 2018Q2, 2018

Net Income

(17.0m)(34.5m)

Depreciation and Amortization

12.0k25.0k

Accounts Receivable

5.0m

Accounts Payable

727.0k25.0k

Cash From Operating Activities

(6.4m)(19.3m)

Purchases of PP&E

(46.0k)(46.0k)

Cash From Investing Activities

(89.7m)(92.5m)

Cash From Financing Activities

138.6m133.4m

Interest Paid

123.0k231.0k

CymaBay Therapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x